Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
kidney disease
Marketing
Travere’s launchpad positions Filspari for fast rollout: analyst
An established sales force and payer authorization criteria will fuel a fast launch for Travere’s Filspari in its new indication, analysts predicted.
Nick Paul Taylor
Apr 24, 2026 10:06am
In another win for rare disease, Travere nabs FDA’s first FSGS nod
Apr 13, 2026 6:25pm
Biogen lays out $5.6B to acquire Apellis
Mar 31, 2026 10:32am
Novartis to seek full IgAN nod for Vanrafia despite ph. 3 miss
Feb 13, 2026 10:52am
Travere's bid to gain new approval for Filspari hits FDA hitch
Jan 14, 2026 11:22am
Hansa's bid to push imlifidase into autoimmune indication flops
Dec 17, 2025 10:11am
